Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine

J. M. Hansen, L. L. Thomsen, R. Marconi, G. Casari, J. Olesen, M. Ashina

Research output: Contribution to journalArticle

Abstract

Familial hemiplegic migraine type 2 (FHM-2) and common types of migraine show phenotypic similarities which may indicate a common neurobiological background. The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a crucial role in migraine pathophysiology. Therefore, we tested the hypothesis that ATP1A2 mutations in patients with FHM-2 are associated with hypersensitivity to NO-cGMP pathway. Eight FHM-2 patients with R202Q, R763C, V138A and L764P mutations and nine healthy controls received intravenous infusions of 0.5 μg kg-1 min-1 glyceryl trinitrate (GTN) over 20 min. We recorded the following variables: headache intensity on a verbal rating scale; mean flow velocity in the middle cerebral artery (V meanMCA) by transcranial Doppler; diameter of the superficial temporal artery (STA) by ultrasound. The primary end-points were differences in incidence of migraine headache and area under the curve (AUC) for headache score during an immediate phase (0-120 min) and a delayed phase (2-14 h) after start of infusion. We found no difference in the incidence of reported migraine between FHM-2 patients, 25% (two out of eight), and controls, 0% (0 out of nine) (95% confidence interval -0.06, 0.56) (P = 0.21). The AUCheadache in the immediate (P = 0.37) and delayed (P = 0.09) phase was not different between patients and controls. The GTN infusion resulted in a biphasic response in patients. During the immediate phase, the median peak headache occurred at 30 min and tended to be higher in patients, 1 (0, 3.8), than in controls, 0 (0, 1) (P = 0.056). During the delayed phase, the median peak headache occurred 4 h after the start of the infusion and was significantly higher in patients, 2.5 (0, 3), than in controls, 0 (0, 0) (P = 0.046). We found no difference in the AUCVmeanMCA (P = 0.77) or AUCSTA (P = 0.53) between FHM-2 patients and controls. GTN infusion failed to induce more migraine in FHM-2 patients than in controls. The pathophysiological pathways underlying migraine headache in FHM-2 may be different from the common types of migraine.

Original languageEnglish
Pages (from-to)367-375
Number of pages9
JournalCephalalgia
Volume28
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Migraine without Aura
Hypersensitivity
Nitric Oxide
Migraine Disorders
Headache
Nitroglycerin
Cyclic GMP
Familial type 2 Hemiplegic migraine
Temporal Arteries
Mutation
Incidence
Middle Cerebral Artery
Intravenous Infusions
Area Under Curve
Confidence Intervals

Keywords

  • Familial hemiplegic migraine
  • Migraine
  • Migraine pathogenesis
  • Neurotransmitters
  • Nitric oxide

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. / Hansen, J. M.; Thomsen, L. L.; Marconi, R.; Casari, G.; Olesen, J.; Ashina, M.

In: Cephalalgia, Vol. 28, No. 4, 04.2008, p. 367-375.

Research output: Contribution to journalArticle

Hansen, J. M. ; Thomsen, L. L. ; Marconi, R. ; Casari, G. ; Olesen, J. ; Ashina, M. / Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. In: Cephalalgia. 2008 ; Vol. 28, No. 4. pp. 367-375.
@article{54e479c2f6284ae18df700e8022b8bb2,
title = "Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine",
abstract = "Familial hemiplegic migraine type 2 (FHM-2) and common types of migraine show phenotypic similarities which may indicate a common neurobiological background. The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a crucial role in migraine pathophysiology. Therefore, we tested the hypothesis that ATP1A2 mutations in patients with FHM-2 are associated with hypersensitivity to NO-cGMP pathway. Eight FHM-2 patients with R202Q, R763C, V138A and L764P mutations and nine healthy controls received intravenous infusions of 0.5 μg kg-1 min-1 glyceryl trinitrate (GTN) over 20 min. We recorded the following variables: headache intensity on a verbal rating scale; mean flow velocity in the middle cerebral artery (V meanMCA) by transcranial Doppler; diameter of the superficial temporal artery (STA) by ultrasound. The primary end-points were differences in incidence of migraine headache and area under the curve (AUC) for headache score during an immediate phase (0-120 min) and a delayed phase (2-14 h) after start of infusion. We found no difference in the incidence of reported migraine between FHM-2 patients, 25{\%} (two out of eight), and controls, 0{\%} (0 out of nine) (95{\%} confidence interval -0.06, 0.56) (P = 0.21). The AUCheadache in the immediate (P = 0.37) and delayed (P = 0.09) phase was not different between patients and controls. The GTN infusion resulted in a biphasic response in patients. During the immediate phase, the median peak headache occurred at 30 min and tended to be higher in patients, 1 (0, 3.8), than in controls, 0 (0, 1) (P = 0.056). During the delayed phase, the median peak headache occurred 4 h after the start of the infusion and was significantly higher in patients, 2.5 (0, 3), than in controls, 0 (0, 0) (P = 0.046). We found no difference in the AUCVmeanMCA (P = 0.77) or AUCSTA (P = 0.53) between FHM-2 patients and controls. GTN infusion failed to induce more migraine in FHM-2 patients than in controls. The pathophysiological pathways underlying migraine headache in FHM-2 may be different from the common types of migraine.",
keywords = "Familial hemiplegic migraine, Migraine, Migraine pathogenesis, Neurotransmitters, Nitric oxide",
author = "Hansen, {J. M.} and Thomsen, {L. L.} and R. Marconi and G. Casari and J. Olesen and M. Ashina",
year = "2008",
month = "4",
doi = "10.1111/j.1468-2982.2008.01542.x",
language = "English",
volume = "28",
pages = "367--375",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine

AU - Hansen, J. M.

AU - Thomsen, L. L.

AU - Marconi, R.

AU - Casari, G.

AU - Olesen, J.

AU - Ashina, M.

PY - 2008/4

Y1 - 2008/4

N2 - Familial hemiplegic migraine type 2 (FHM-2) and common types of migraine show phenotypic similarities which may indicate a common neurobiological background. The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a crucial role in migraine pathophysiology. Therefore, we tested the hypothesis that ATP1A2 mutations in patients with FHM-2 are associated with hypersensitivity to NO-cGMP pathway. Eight FHM-2 patients with R202Q, R763C, V138A and L764P mutations and nine healthy controls received intravenous infusions of 0.5 μg kg-1 min-1 glyceryl trinitrate (GTN) over 20 min. We recorded the following variables: headache intensity on a verbal rating scale; mean flow velocity in the middle cerebral artery (V meanMCA) by transcranial Doppler; diameter of the superficial temporal artery (STA) by ultrasound. The primary end-points were differences in incidence of migraine headache and area under the curve (AUC) for headache score during an immediate phase (0-120 min) and a delayed phase (2-14 h) after start of infusion. We found no difference in the incidence of reported migraine between FHM-2 patients, 25% (two out of eight), and controls, 0% (0 out of nine) (95% confidence interval -0.06, 0.56) (P = 0.21). The AUCheadache in the immediate (P = 0.37) and delayed (P = 0.09) phase was not different between patients and controls. The GTN infusion resulted in a biphasic response in patients. During the immediate phase, the median peak headache occurred at 30 min and tended to be higher in patients, 1 (0, 3.8), than in controls, 0 (0, 1) (P = 0.056). During the delayed phase, the median peak headache occurred 4 h after the start of the infusion and was significantly higher in patients, 2.5 (0, 3), than in controls, 0 (0, 0) (P = 0.046). We found no difference in the AUCVmeanMCA (P = 0.77) or AUCSTA (P = 0.53) between FHM-2 patients and controls. GTN infusion failed to induce more migraine in FHM-2 patients than in controls. The pathophysiological pathways underlying migraine headache in FHM-2 may be different from the common types of migraine.

AB - Familial hemiplegic migraine type 2 (FHM-2) and common types of migraine show phenotypic similarities which may indicate a common neurobiological background. The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a crucial role in migraine pathophysiology. Therefore, we tested the hypothesis that ATP1A2 mutations in patients with FHM-2 are associated with hypersensitivity to NO-cGMP pathway. Eight FHM-2 patients with R202Q, R763C, V138A and L764P mutations and nine healthy controls received intravenous infusions of 0.5 μg kg-1 min-1 glyceryl trinitrate (GTN) over 20 min. We recorded the following variables: headache intensity on a verbal rating scale; mean flow velocity in the middle cerebral artery (V meanMCA) by transcranial Doppler; diameter of the superficial temporal artery (STA) by ultrasound. The primary end-points were differences in incidence of migraine headache and area under the curve (AUC) for headache score during an immediate phase (0-120 min) and a delayed phase (2-14 h) after start of infusion. We found no difference in the incidence of reported migraine between FHM-2 patients, 25% (two out of eight), and controls, 0% (0 out of nine) (95% confidence interval -0.06, 0.56) (P = 0.21). The AUCheadache in the immediate (P = 0.37) and delayed (P = 0.09) phase was not different between patients and controls. The GTN infusion resulted in a biphasic response in patients. During the immediate phase, the median peak headache occurred at 30 min and tended to be higher in patients, 1 (0, 3.8), than in controls, 0 (0, 1) (P = 0.056). During the delayed phase, the median peak headache occurred 4 h after the start of the infusion and was significantly higher in patients, 2.5 (0, 3), than in controls, 0 (0, 0) (P = 0.046). We found no difference in the AUCVmeanMCA (P = 0.77) or AUCSTA (P = 0.53) between FHM-2 patients and controls. GTN infusion failed to induce more migraine in FHM-2 patients than in controls. The pathophysiological pathways underlying migraine headache in FHM-2 may be different from the common types of migraine.

KW - Familial hemiplegic migraine

KW - Migraine

KW - Migraine pathogenesis

KW - Neurotransmitters

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=40349085497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349085497&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2008.01542.x

DO - 10.1111/j.1468-2982.2008.01542.x

M3 - Article

C2 - 18294248

AN - SCOPUS:40349085497

VL - 28

SP - 367

EP - 375

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 4

ER -